BioCryst Pharmaceuticals (NASDAQ:BCRX) PT Raised to $15.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price increased by JMP Securities from $14.00 to $15.00 in a report released on Tuesday, Benzinga reports. The firm presently has a “market outperform” rating on the biotechnology company’s stock. JMP Securities’ target price would indicate a potential upside of 194.12% from the stock’s previous close.

Other research analysts have also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Needham & Company LLC restated a “buy” rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $5.10 on Tuesday. The stock has a market cap of $1.05 billion, a PE ratio of -4.77 and a beta of 1.96. The business has a fifty day moving average of $4.89 and a two-hundred day moving average of $5.45. BioCryst Pharmaceuticals has a 52-week low of $4.03 and a 52-week high of $8.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The company had revenue of $92.80 million for the quarter, compared to the consensus estimate of $85.62 million. The firm’s revenue was up 34.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.28) earnings per share. Analysts predict that BioCryst Pharmaceuticals will post -0.69 earnings per share for the current year.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fifth Third Bancorp increased its position in BioCryst Pharmaceuticals by 17,500.0% in the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 3,500 shares during the period. China Universal Asset Management Co. Ltd. increased its position in BioCryst Pharmaceuticals by 96.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 2,388 shares during the period. Quarry LP acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth about $54,000. Tower Research Capital LLC TRC grew its position in shares of BioCryst Pharmaceuticals by 131.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock worth $62,000 after buying an additional 5,912 shares during the period. Finally, JGP Global Gestao de Recursos Ltda. acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth about $64,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.